Charles Schwab’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-343,133
| Closed | -$25.8M | – | 3585 |
|
|
2022
Q2 | $25.8M | Sell |
343,133
-8,061
| -2% | -$358K | 0.01% | 1211 |
|
|
2022
Q1 | $9.43M | Buy |
351,194
+6,399
| +2% | +$215K | ﹤0.01% | 1992 |
|
|
2021
Q4 | $16.4M | Buy |
344,795
+8,185
| +2% | +$366K | ﹤0.01% | 1722 |
|
|
2021
Q3 | $22.4M | Buy |
336,610
+16,916
| +5% | +$1.21M | 0.01% | 1496 |
|
|
2021
Q2 | $24.9M | Buy |
319,694
+26,467
| +9% | +$1.96M | 0.01% | 1408 |
|
|
2021
Q1 | $27.7M | Buy |
293,227
+23,984
| +9% | +$2.85M | 0.01% | 1252 |
|
|
2020
Q4 | $32.8M | Buy |
269,243
+34,421
| +15% | +$3.77M | 0.01% | 1042 |
|
|
2020
Q3 | $20.5M | Buy |
234,822
+85,554
| +57% | +$5.96M | 0.01% | 1187 |
|
|
2020
Q2 | $9.64M | Buy |
149,268
+31,378
| +27% | +$1.81M | ﹤0.01% | 1671 |
|
|
2020
Q1 | $5.26M | Buy |
117,890
+1,625
| +1% | +$86.3K | ﹤0.01% | 1807 |
|
|
2019
Q4 | $7.24M | Buy |
116,265
+44,962
| +63% | +$2.14M | ﹤0.01% | 1834 |
|
|
2019
Q3 | $2.68M | Buy |
71,303
+20,397
| +40% | +$888K | ﹤0.01% | 2283 |
|
|
2019
Q2 | $2.07M | Buy |
+50,906
| New | +$1.82M | ﹤0.01% | 2360 |
|
Charles Schwab's TPTX Position: Q3 2022 in Review
Charles Schwab sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 343,133 shares — an estimated $25.8M sold.
Charles Schwab first reported a position in TPTX in Q2 2019 and held it in 13 quarters. The position peaked at $32.8M in Q4 2020. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.
- Charles Schwab reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
- Charles Schwab sold 343,133 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $25.8M.
- Charles Schwab first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 13 quarters.
- Charles Schwab's Turning Point Therapeutics, Inc. Common Stock position peaked at $32.8M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.
Based on Charles Schwab's 13F filing for Q3 2022, filed 14 Nov 2022.